On 28 April 2026, the UK Medicines for Human Use (Clinical Trials) (Amendment) Regulations 2025 took full effect, introducing the most significant update to UK clinical trial legislation in more than two decades.
For sponsors planning or running UK clinical trials of investigational medicinal products (CTIMPs), the change is more than a legal update. It affects how applications are prepared, how approval timelines are managed, how study changes are classified, and how transparency and participant communication are built into trial delivery.
The amended framework is intended to support a more proportionate, modern and internationally aligned clinical trial environment. In practice, its benefits will depend on how well sponsors translate the new requirements into operational planning before submission and during conduct.
At a glance: Five Sponsor Implications
A more structured approval environment
Combined MHRA and Research Ethics Committee submissions have been in place for several years and efficiencies have been seen. For sponsors, this creates a more joined-up approval process, but it also places more pressure on submission quality and response readiness.
A valid application can receive a combined decision within 30 calendar days of validation. If further information is requested, the sponsor has up to 60 calendar days to respond, followed by a decision within 10 calendar days of the response being submitted. The practical point is clear: the statutory pathway has defined steps, but the operational timeline is partly sponsor-driven.
This makes early cross-functional preparation essential. Protocol quality, Investigator’s Brochure readiness, IMP and non-investigational medicinal product information, labelling content, participant facing information, registry planning and study documentation should be aligned before submission, not resolved after validation or during RFI response.
Notifiable trials: proportionate review still requires regulatory judgement
The amended regulations introduce a notifiable trial route for certain lower-risk clinical trials. Where the trial meets at least one inclusion condition and none of the exclusion criteria apply, the application may be eligible for automatic authorisation by the licensing authority.
This is not simply an administrative shortcut. Sponsors remain responsible for assessing whether the trial is notifiable, documenting the justification and including the relevant statement and supporting form in the application package. The trial still proceeds through the combined review process, and the trial cannot proceed until the combined decision confirms approval or approval with conditions.
If a trial is eligible for automatic authorisation but is incorrectly submitted for full review, the application may be invalidated and require resubmission. For sponsors, notifiable trial assessment should therefore sit within regulatory strategy, quality review and submission planning.
Modifications: terminology now has operational consequences
The amended UK framework replaces the term “substantial amendment” with “substantial modification”, aligning UK language more closely with international clinical trial terminology. More importantly, the new categories determine the approval pathway, review timeline and implementation controls.
Modifications may be substantial modifications, modifications of an important detail or minor modifications. Substantial modifications are then assessed as Route A or Route B. Route A applies to changes likely to have a substantial impact on participant safety or rights, or on the reliability or robustness of trial data. Route B applies to defined substantial modifications that may be eligible for automatic licensing authority approval, provided the relevant criteria are met and no new significant IMP safety concerns are known.
This classification needs to be built into trial governance. Study teams should know how to assess the change, document the rationale, identify the correct route and determine when implementation can occur. For ongoing studies, this may require updates to internal trackers, sponsor-CRO communication pathways and escalation processes.
Transparency is now a start-up and governance issue
The amended regulations give clinical trial transparency a stronger legal basis in the UK. Sponsors need to plan trial registration before the first UK participant is recruited and within the required regulatory timeframe. They also need to plan publication of summary results and the offer to share understandable results with participants or other relevant people.
This changes how transparency should be managed. It is no longer only an end-of-study activity. Registry strategy, first UK participant notification should be managed during start-up and lay summary planning, publication responsibilities and participant communication routes planned well in advance of the end of study.
For multi-country studies, sponsors should also consider how UK transparency obligations interact with global registry plans and internal publication governance. Registering in more than one registry can create additional results-publication obligations, so registry strategy should be intentional rather than automatic.
Labelling and ongoing study readiness
The amended regulations also affect IMP labelling expectations. Sponsors with ongoing UK CTIMPs should review whether currently approved UK labels remain aligned with the amended requirements, especially where new IMP batches are manufactured after 28 April 2026.
If label updates are needed, sponsors should risk-assess whether the change is substantial or minor and determine whether a Route A substantial modification is required before implementation. This has practical implications for supply planning, QP certification, regulatory submissions, site readiness and critical-path study timelines.
Because labelling sits at the intersection of regulatory, quality, supply and clinical operations, the review should not sit with one function only. It should be treated as an operational readiness workstream for both ongoing and planned UK studies.
Simplified consent: a proportionate option for selected trials
The amended regulations also introduce the option to use simplified arrangements for seeking and evidencing informed consent in selected clinical trials that meet specific conditions. This may support more proportionate approaches in appropriate low-intervention settings, but it needs to be justified and described in the protocol.
For sponsors, the main consideration is not whether simplified consent is available in principle, but whether the trial design, IMP use, routine-care context and participant journey support its use in practice. As with notifiable trials, proportionate routes require careful documentation.
What sponsors should do now
Sponsors with ongoing or planned UK CTIMPs should consider a structured readiness review across the following areas:
How Ergomed Clinical Research can support
Ergomed Clinical Research supports biotech and pharmaceutical sponsors across complex clinical development programs, including UK and global trial planning, regulatory strategy, start-up, clinical operations, medical oversight, patient engagement and study delivery.
As sponsors adapt to the amended UK clinical trial regulations, experienced regulatory and operational support can help translate new requirements into workable execution plans. This includes submission planning, start-up strategy, notifiable trial assessment, modification governance, transparency readiness, labelling coordination and ongoing trial oversight.
For sponsors operating under compressed timelines or managing complex studies across multiple countries, the priority is not only understanding the regulation. It is building a delivery model that keeps regulatory expectations, patient safety, site readiness and study momentum connected from the outset.
Sources:
MHRA – apply for approval in the UK: https://www.gov.uk/guidance/clinical-trials-for-medicines-apply-for-approval-in-the-uk
MHRA – notifiable trials: https://www.gov.uk/guidance/clinical-trials-for-medicines-notifiable-trials
MHRA – modifying a clinical trial approval: https://www.gov.uk/guidance/clinical-trials-for-medicines-modifying-a-clinical-trial-approval
MHRA – labelling: https://www.gov.uk/guidance/clinical-trials-for-medicines-labelling
HRA – clinical trials regulations reform: https://www.hra.nhs.uk/planning-and-improving-research/policies-standards-legislation/clinical-trials-investigational-medicinal-products-ctimps/clinical-trial-regulations-reform/